8-K: IMAC Holdings Terminates Merger Agreement with Theralink After Asset Acquisition

IMAC Holdings terminated its merger agreement with Theralink Technologies after acquiring Theralink's assets through a settlement agreement.

Summary

• IMAC Holdings, Inc. acquired the assets of Theralink Technologies, Inc. on May 1, 2024, as part of a settlement agreement due to Theralink's debt default.
• The asset acquisition made the previously planned merger unnecessary, leading to the termination of the merger agreement on May 6, 2024.
• IMAC Holdings will issue preferred stock to Theralink and/or its debt holders after a third-party valuation of Theralink's business.
• The company is withdrawing the Registration Statement on Form S-4 related to the terminated merger agreement.
• IMAC Holdings is transitioning key employees from Theralink to stabilize operations and commercialize Theralink's precision medicine technology.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company has successfully acquired assets and streamlined its strategy, but there are still risks associated with integration and valuation.

Positives

• IMAC Holdings has successfully acquired Theralink's assets, gaining access to their precision medicine technology.
• The termination of the merger agreement streamlines the process and avoids a lengthy regulatory approval process.
• The settlement allows Theralink's advancements in breast cancer diagnostics to continue under IMAC Holdings.
• IMAC Holdings is positioned to commercialize Theralink's services without obstruction.

Negatives

• The merger agreement was terminated, indicating a change in the original strategic plan.
• The issuance of preferred stock is contingent on a third-party valuation, which introduces uncertainty.

Risks

• The integration of Theralink's assets and employees into IMAC Holdings may present challenges.
• The third-party valuation of Theralink's business could impact the value of the preferred stock issued.
• There is a risk associated with the transition of key employees and the stabilization of business operations.

Future Outlook

IMAC Holdings plans to commercialize Theralink's precision medicine technology and integrate key employees to stabilize operations.

Management Comments

• Jeff Ervin, Chief Executive Officer of IMAC Holdings, stated that the settlement allows Theralink's advancements to survive and thrive at IMAC.
• Jeff Ervin also mentioned that they are transitioning key employees to stabilize the business and capitalize on the team's success.

Industry Context

This announcement reflects a shift in strategy for IMAC Holdings, moving from a merger to an asset acquisition, which is not uncommon in the biotech and healthcare sectors where companies often seek to acquire specific technologies or assets.

Comparison to Industry Standards

• Asset acquisitions are a common strategy in the biotech industry, often used to gain access to specific technologies or intellectual property, similar to how companies like Roche have acquired smaller biotech firms for their drug pipelines.
• The termination of a merger agreement after an asset acquisition is not unusual, as seen in cases where companies like Pfizer have restructured deals to focus on specific assets rather than entire entities.
• The issuance of preferred stock as part of a settlement is a common practice in distressed situations, similar to how companies like Kodak have used preferred stock to restructure debt.

Stakeholder Impact

• Shareholders of IMAC Holdings may see a positive impact from the acquisition of Theralink's assets and the streamlined strategy.
• Employees of Theralink will be transitioned to IMAC Holdings, potentially impacting their roles and responsibilities.
• Customers of Theralink may benefit from the continued commercialization of their services under IMAC Holdings.

Next Steps

• IMAC Holdings will complete a third-party valuation of Theralink's business.
• IMAC Holdings will issue preferred stock to Theralink and/or its debt holders.
• IMAC Holdings will transition key employees from Theralink.
• IMAC Holdings will commercialize Theralink's precision medicine technology.

Key Dates

Keywords

merger termination, asset acquisition, settlement agreement, precision medicine, Theralink, IMAC Holdings, preferred stock, breast cancer diagnostics, proteomic analysis